Pedro Nazareth Aguiar1, Hakaru Tadokoro1, Gislaine Fernandes da Silva1, Mayndra Mychelle Landgraf1, Carmelia Maria Noia Barreto1, Bruno Andraus Filardi1, Gilberto de Lima Lopes2,3, Pedro Oliveira4, Ramon Andrade de Mello5,6. 1. Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil. 2. Johns Hopkins Singapore, City of Singapore, Singapore. 3. Oncoclínicas of Brazil, HCor, São Paulo, Brazil. 4. Department of Population Studies, Abel Salazar Biomedical Institute, University of Porto, Porto, Portugal. 5. Department of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal. 6. Division of Oncology, Department of Biomedical Sciences & Medicine, University of Algarve, Campus de Gambelas, Edifício 7, ala Nascente, 3º Andar, 8005-139, Faro, Portugal.
Abstract
AIM: Concomitant chemoradiotherapy (with cisplatin or carboplatin) is an option of definitive treatment for squamous head and neck cancer. We aimed to perform a meta-analysis comparing those two platinum agents. MATERIALS & METHODS: We carried out a systematic search on English literature between 1990 and 17 April 2015 according to the Cochrane review guidelines. RESULTS: Five of 60 studies fulfilled inclusion criteria with 491 patients. There was no difference in response rate. Cisplatin tends to be more active systemically than carboplatin, without statistically significance; 5-year survival rate: 30 and 27%, respectively (p = 0.33). CONCLUSION: Despite the trend to improved outcomes in using cisplatin, carboplatin is also active and can be a reasonable option to treat patients.
AIM: Concomitant chemoradiotherapy (with cisplatin or carboplatin) is an option of definitive treatment for squamous head and neck cancer. We aimed to perform a meta-analysis comparing those two platinum agents. MATERIALS & METHODS: We carried out a systematic search on English literature between 1990 and 17 April 2015 according to the Cochrane review guidelines. RESULTS: Five of 60 studies fulfilled inclusion criteria with 491 patients. There was no difference in response rate. Cisplatin tends to be more active systemically than carboplatin, without statistically significance; 5-year survival rate: 30 and 27%, respectively (p = 0.33). CONCLUSION: Despite the trend to improved outcomes in using cisplatin, carboplatin is also active and can be a reasonable option to treat patients.
Entities:
Keywords:
carboplatin; chemoradiotherapy; chemotherapy; cisplatin; head and neck
Authors: Muhammad Furqan; Travis P Snyders; Mohammed U Saqlain; Sarah L Mott; Douglas Laux; Anthony Snow; Carryn M Anderson; John M Watkins; Gerald H Clamon Journal: Cancer Med Date: 2019-04-09 Impact factor: 4.452